Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 7/20 | 0.43 |
| ▸ | PPARG | P37231 | 6/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994942 | 1.00 | ACE (0.47) | ACEITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL27998523 | 0.89 | CTSK (0.44) | ACEITGB3ITGA2BPPARAPPARG | |
| SCHEMBL478317 | 0.89 | KLK5 (0.43) | ACEITGA4ITGB7CTSKCTSS | |
| SCHEMBL478315 | 0.89 | KLK5 (0.43) | ACEITGA4ITGB7CTSKCTSS | |
| SCHEMBL1196676 | 0.85 | ACE (0.49) | ACEITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL1196678 | 0.85 | ACE (0.49) | ACEITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL24189724 | 0.83 | ACE (0.47) | ACEITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL29015319 | 0.83 | ACE (0.47) | ACEITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL10264093 | 0.83 | ACE (0.37) | ACEITGA4ITGB7CTSKCTSS | |
| SCHEMBL31304927 | 0.77 | PPARA (0.39) | PPARAPPARGCTSKCTSSPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| CN-101784516-B | Dipeptide analogs as coagulation factor inhibitors | BRISTOL MYERS SQUIBB CO | 2014-07-02 | — | — | CN | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2265601-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | disclosed |
| CN-101784516-A | Dipeptide analogs as coagulation factor inhibitors | BRISTOL MYERS SQUIBB CO | 2010-07-21 | — | — | CN | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| WO-2009114677-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | ACE 112/4885ITGB3 3113/4885ITGA2B 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.